Kiniksa Pharmaceuticals to Report First Quarter 2022 Financial Results on May 3, 2022
Rhea-AI Summary
Kiniksa Pharmaceuticals, Ltd. (KNSA) will hold a conference call on May 3, 2022, at 8:30 a.m. Eastern Time to discuss its Q1 2022 financial results and corporate activities. A live webcast will be available on their website, with a replay accessible 48 hours post-event. Kiniksa focuses on developing therapeutic medicines for debilitating diseases, with a portfolio that includes ARCALYST®, vixarelimab, KPL-404, and mavrilimumab, targeting significant unmet medical needs through innovative biologic mechanisms.
Positive
- Kiniksa's focus on developing therapeutics for unmet medical needs.
- Portfolio includes promising assets like vixarelimab and KPL-404.
Negative
- None.
Insights
Analyzing...
HAMILTON, Bermuda, May 02, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, May 3, 2022, at 8:30 a.m. Eastern Time to report its first quarter 2022 financial results and corporate activities.
A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will also be available on Kiniksa’s website within approximately 48 hours of the event. The conference call can be accessed by dialing (866) 614-0636 (U.S. and Canada) or (409) 231-2053 (international) using conference ID number 7787467.
About Kiniksa
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s portfolio assets, ARCALYST®, vixarelimab, KPL-404, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target underserved conditions, and offer the potential for differentiation. These assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visit www.kiniksa.com.
ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc.
Every Second Counts!®
Kiniksa Investor and Media Contact
Rachel Frank
(339) 970-9437
rfrank@kiniksa.com
FAQ
What time is Kiniksa's Q1 2022 earnings call?
Where can I watch Kiniksa's earnings call live?
What are Kiniksa's key products?
What is the focus of Kiniksa Pharmaceuticals?
